Melane Sampson, Author at BioTuesdays

Developments

Karyopharm completes enrollment of Phase 3 SENTRY trial in MF

Karyopharm Therapeutics (NASDAQ: KPTI) has announced enrollment completion in its Phase 3 SENTRY trial, designed to evaluate selinexor in combination with ruxolitinib in JAKi-naïve myelofibrosis (MF) patients. According...

September 10, 2025

Developments

FDA grants Greenwich fast track designation for GLSI-100

Greenwich LifeSciences (NASDAQ: GLSI) announced that the FDA has granted GLSI-100 fast track designation for the treatment of patients with HLA-A*02 genotype and HER2-positive breast cancer who have completed treatment...

September 10, 2025

Executive Moves

MedX appoints Dr. Paul Matts as strategic advisor

MedX Health (TSXV: MDX) has announced the appointment of Dr. Paul J. Matts, internationally recognized skin scientist, biochemist, and educator, as strategic advisor. Dr. Matts is an academic and industry leader, as...

September 9, 2025

Feature

Micoy engineering therapeutic decoys to block rogue autoantibodies

Closely held Micoy Therapeutics is advancing novel, first-in-class therapeutics to target harmful autoantibodies that induce immunodeficiency by inhibiting immune signaling molecules—type I interferons—which are...

September 9, 2025

Developments

Perimeter Joins ASBrS Industry Relations Council

Perimeter Medical Imaging AI (TSX-V:PINK; OTCQX: PYNKF) announced that it has joined the American Society of Breast Surgeons (ASBrS) Industry Relations Council (IRC). The ASBrS is the primary leadership organization for...

September 8, 2025

Developments

iMDX launches novel registry database; reports positive strategic update

Insight Molecular Diagnostics (iMDX) (NASDAQ: IMDX) has announced a positive strategic update and novel registry to gather real-world data on patient experiences and outcomes concerning its flagship kidney transplant...

September 8, 2025

Executive Moves

Tatjana Mitchell joins Evolus as CFO

Evolus (NASDAQ: EOLS) has announced the appointment of Tatjana Mitchell as chief financial officer (CFO), effective today. Ms. Mitchell brings more than 20 years of strategic and operational finance leadership across...

September 8, 2025

Developments

Pasithea enrolls Cohort 2 for trial of PAS-004 in NF1 after SRC review

Pasithea Therapeutics (NASDAQ: KTTA) announced that the Safety Review Committee (SRC) has recommended its Phase 1/1b open label study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PAS-004...

September 8, 2025

Developments

Firefly partners with HealingMaps to offer cognitive electrophysiology analytics to 2500+ clinics across North America

Firefly Neuroscience (NASDAQ: AIFF) announced a new partnership with HealingMaps the leading directory for ketamine, psychedelic-assisted therapy, and transcranial magnetic stimulation (TMS) clinics, and Advanced...

September 5, 2025

Developments

Health Canada grants Palisade NOL for trial of PALI-2108 in FSCD

Palisade Bio (NASDAQ: PALI) has announced receiving a No Objection Letter (NOL) from Health Canada for its clinical trial application to evaluate PALI-2108, a first-in-class, ileocolonic-targeted PDE4 B/D inhibitor, in...

September 5, 2025

Author - Melane Sampson

Karyopharm completes enrollment of Phase 3 SENTRY trial in MF

FDA grants Greenwich fast track designation for GLSI-100

MedX appoints Dr. Paul Matts as strategic advisor

Micoy engineering therapeutic decoys to block rogue autoantibodies

Perimeter Joins ASBrS Industry Relations Council

iMDX launches novel registry database; reports positive strategic update

Tatjana Mitchell joins Evolus as CFO

Pasithea enrolls Cohort 2 for trial of PAS-004 in NF1 after SRC review

Firefly partners with HealingMaps to offer cognitive electrophysiology analytics to 2500+ clinics across North America

Health Canada grants Palisade NOL for trial of PALI-2108 in FSCD

Subscribe